항비만약 시장 규모, 점유율, 성장 분석 : 약 유형별, 작용별, 투여별, 지역별 - 산업 예측(2025-2032년)

Global Anti Obesity Drugs Market size was valued at USD 3.7 billion in 2023 and is poised to grow from USD 4.67 billion in 2024 to USD 30.26 billion by 2032, growing at a CAGR of 26.3% during the forecast period (2025-2032).

The World Obesity Federation forecasts that obesity-related costs will surge by over 50%, reaching approximately $1.2 trillion by the end of 2025. This escalation emphasizes the pharmaceutical industry's focus on developing effective solutions to combat obesity. As the patient population grows and treatment rates remain low, there are significant opportunities for new entrants in the market. Initiatives aimed at educating the public about obesity and the establishment of supportive reimbursement policies are likely to drive product demand. The COVID-19 pandemic has paradoxically boosted sales of approved anti-obesity medications, as heightened health risks associated with obesity have prompted health organizations to issue management guidelines. Furthermore, increased sedentary behavior due to lockdowns has intensified the need for obesity treatments, potentially enhancing market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Anti Obesity Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Anti Obesity Drugs Market Segmental Analysis

Global Anti Obesity Drugs Market is segmented by Drug Type, Action, Administration, Distribution Channel and region. Based on Drug Type, the market is segmented into Prescription Drug and Over the Counter Drugs. Based on Action, the market is segmented into Centrally Acting Anti-Obesity Drugs and Peripherally Acting Anti-Obesity Drugs. Based on Administration, the market is segmented into Oral Route and Subcutaneous Route. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Anti Obesity Drugs Market

The global anti-obesity drugs market is significantly driven by escalating concerns regarding effective obesity management, propelled by the alarming rise in obesity rates among populations worldwide. Currently, the World Obesity Federation reports staggering figures of approximately 650 million adults and 120 million children grappling with obesity, leading to an annual expenditure of around US$ 2 trillion for obesity-related healthcare. Furthermore, the Centers for Disease Control and Prevention (CDC) indicates that 42.5% of adults in the United States are classified as obese. This escalating awareness, particularly in emerging economies, about the necessity of timely weight management is anticipated to further fuel the demand for anti-obesity medications in the market over the coming years.

Restraints in the Global Anti Obesity Drugs Market

The Global Anti-Obesity Drugs market faces significant restraints, despite the increasing prevalence of obesity worldwide. Treatment rates remain low, primarily due to a lack of awareness regarding weight management and widespread misconceptions about obesity. Our research indicates that only 2% of individuals with obesity receive prescription medication for their condition, reflecting low acceptance of these drugs, which hampers market growth. Additionally, the market is constrained by the limited number of key companies focused on developing obesity treatments and the adverse effects associated with these medications, further impeding broader adoption and expansion of anti-obesity solutions.

Market Trends of the Global Anti Obesity Drugs Market

The Global Anti-Obesity Drugs market is witnessing a significant trend towards the development of dual-action therapeutic compounds aimed at simultaneously addressing both Type 2 diabetes mellitus and obesity. This burgeoning focus is driven by the alarming increase in obesity rates and the corresponding prevalence of Type 2 diabetes, prompting pharmaceutical companies and researchers to innovate and create effective medications that tackle these interrelated health issues. With unhealthy dietary habits, sedentary lifestyles, and a growing obese population persisting as key challenges, the market is poised for substantial growth in the coming years, presenting lucrative opportunities for stakeholders in the healthcare sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Patent Analysis
• Regulatory Analysis

Global Anti Obesity Drugs Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Prescription Drug
• Over the Counter Drugs

Global Anti Obesity Drugs Market Size by Action & CAGR (2025-2032)

• Market Overview
• Centrally Acting Anti-Obesity Drugs
• Peripherally Acting Anti-Obesity Drugs

Global Anti Obesity Drugs Market Size by Administration & CAGR (2025-2032)

• Market Overview
• Oral Route
• Subcutaneous Route

Global Anti Obesity Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Anti Obesity Drugs Market Size & CAGR (2025-2032)

• North America (Drug Type, Action, Administration, Distribution Channel)
  • US
  • Canada
• Europe (Drug Type, Action, Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Action, Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Action, Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Action, Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Currax Pharmaceuticals LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK/Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rhythm Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gelesis Holdings, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orexigen Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zafgen Inc. (USA) (Ceased operations)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VIVUS LLC (USA) (Acquired by Currax Pharmaceuticals)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cheplapharm Arzneimittel GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KVK Tech Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations